Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Verona Pharma (VRNA – Research Report), boosting the price target to ...

In a report released today, Thomas Shrader from BTIG maintained a Buy rating on Verona Pharma (VRNA – Research Report), with a price ...

Q3 2024 Earnings Call Transcript November 4, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.08819, ...

Verona Pharma isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are ...

Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company ...

Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ETCompany ParticipantsDavid Zaccardelli - President and ...

Skadden Arps Slate Meagher & Flom has hired the head of Latham & Watkins' London IP practice, marking the latest in a string ...

Highlights:,Ohtuvayre™ generates $5.6 million in net sales in its first seven weeks, signaling a strong market entry.,October ...

Verona Pharma has been on an incredible upward trajectory, boasting a 91.50% increase year-to-date. In contrast, the MSCI World Index has only managed a 15.50% gain in the same period. This stark ...

Verona Pharma (NASDAQ:VRNA) is scheduled to announce Q3 earnings results on Monday, November 4th, before market open. The consensus EPS Estimate is -$0.41 and the consensus Revenue Estimate is $2.01M.